XOMA Corp Given Average Recommendation of “Buy” by Analysts (NASDAQ:XOMA)
Shares of XOMA Corp (NASDAQ:XOMA) have earned a consensus recommendation of “Buy” from the ten ratings firms that are covering the company, Analyst Ratings News reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $9.00.
Shares of XOMA Corp (NASDAQ:XOMA) traded up 3.79% on Friday, hitting $3.56. 546,578 shares of the company’s stock traded hands. XOMA Corp has a one year low of $3.31 and a one year high of $9.57. The stock has a 50-day moving average of $4.63 and a 200-day moving average of $5.90. The company’s market cap is $379.4 million.
XOMA Corp (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.06. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $7.40 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. The company’s quarterly revenue was down 63.9% on a year-over-year basis. Analysts expect that XOMA Corp will post $-0.69 EPS for the current fiscal year.
XOMA has been the subject of a number of recent research reports. Analysts at MLV & Co
upgraded shares of XOMA Corp from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. They now have a $7.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at TheStreet downgraded shares of XOMA Corp from a “hold” rating to a “sell” rating in a research note on Friday, March 7th.
XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.